CVS
CVS Health Corp
CVS Health Corp historical holders
total: 20
Fairfax Financial Holdings CVS Health Corp transactions over time
- Total transactions:
- 4
- New positions:
- 2
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2024 Q4
- Held for:
- 6 quarters
- Latest activity:
- 2024 Q4
Prem Watsa has been an institutional investor in CVS Health Corp (CVS) since 2019 Q4. According to 2026 Q1 report, Prem Watsa holds 2,712,000 shares with a market value of roughly $194.78M representing 10.03% of their equity portfolio. The fund/company first acquired CVS in 2019 Q4, initially purchasing 26,500 shares. Prem Watsa later completely sold out the position and reinvested in CVS again in 2024 Q4. Since the initial investment, Fairfax Financial Holdings has made 3 more transactions in this position.
Does Prem Watsa still hold CVS?
Yes, Prem Watsa continues to hold CVS Health Corp (CVS). According to their 2026 Q1 report, they maintain a position of 2,712,000 shares valued at approximately $194.78M, representing 10.03% of their equity portfolio.
When did Prem Watsa first invest in CVS?
Prem Watsa first invested in CVS Health Corp (CVS) in 2019 Q4 at the reported quarter-end price of $74.26 per share, acquiring 26,500 shares in their initial purchase.
What is Prem Watsa's average cost basis for CVS?
Based on historical transaction data, Prem Watsa's estimated cost basis for CVS Health Corp (CVS) is approximately $44.89 per share. This represents their average reported price* across all buy transactions.
Has Prem Watsa reinvested in CVS after selling?
Yes, Prem Watsa has shown renewed interest in CVS Health Corp (CVS). After completely selling their position, they reinitiated an investment in 2024 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $44.89
CVS transactions history by Fairfax Financial Holdings
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
7.82%
|
2,712,000
|
$44.89
|
$121,741,680
|
new
|
+7.82%
|
|
2024 Q2
|
0.00%
|
0
|
$79.73
|
|
-100% (-15,000)
|
-0.1%
|
|
2022 Q2
|
0.05%
|
15,000
|
$92.67
|
$1,390,000
|
-43.40% (-11,500)
|
-0.04%
|
|
2019 Q4
|
0.08%
|
$74.26
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.